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Mitochondrial dysfunctions are a known pathogenetic mechanism of a number of neurological 
and psychiatric disorders. At the same time, mutations in genes encoding for components of 
the mitochondrial respiratory chain cause mitochondrial diseases, which commonly exhibit 
neurological symptoms. Mitochondria are therefore critical for the functionality of the human 
nervous system. The importance of mitochondria stems from their key roles in cellular 
metabolism, calcium handling, redox and protein homeostasis, and overall cellular 
homeostasis through their dynamic network. Here, we describe how the use of pluripotent 
stem cells (PSCs) may help addressing the physiological and pathological relevance of 
mitochondria for the human nervous system. PSCs allow the generation of patient-derived 
neurons and glia and the identification of gene-specific and mutation-specific cellular 
phenotypes via genome engineering approaches. We discuss the recent advances in PSC-
based modeling of brain diseases and the current challenges of the field. We anticipate that 
the careful use of PSCs will improve our understanding of the impact of mitochondria in 




Mitochondria are intracellular organelles that are present in multiple copies in all nucleated 
cells. They contain their own genome and are maternally inherited (Dyall et al., 2004). The 
major function of mitochondria is to provide energy in the form of ATP through the process 
of oxidative phosphorylation (OxPhos). OxPhos occurs through the action of five protein 
complexes -known as respiratory chain (RC) complexes- localized in the mitochondrial inner 
membrane. Complexes I-IV transfer electrons and at the same time they expel protons into the 
space between the inner and outer mitochondrial membrane. This generates a proton gradient 
across the inner membrane that is known as mitochondrial membrane potential (MMP). The 
energy stored in this gradient is used by Complex V to produce ATP by allowing the entry of 
protons into the mitochondrial matrix (Vafai and Mootha, 2012). 
In addition to bioenergetics, mitochondria are involved in the metabolism of fatty 
acids, amino acids, and steroids, as well as in numerous signaling pathways such as apoptosis, 
calcium homeostasis, and in the generation of reactive oxygen species (ROS) (Dyall et al., 
2004). Hence, dysfunction of mitochondria can impact an array of cellular homeostatic 
processes. Mitochondrial impairment will cause more detrimental consequences on cells that 
are strictly dependent on their functionality.  
In this review, we first describe the physiological and pathological importance of 
mitochondria for the human brain. The human nervous system is highly complex and 
significantly different from that of other species. In order to understand the mitochondrial 
contribution to human brain function and to the pathogenesis of brain diseases, it is important 
to investigate human brain cells, which can now be generated in vitro from human pluripotent 
stem cells (PSCs). In the second part of the review, we discuss the promises and challenges of 
PSCs for understanding the role of mitochondria in the function and dysfunction of the human 
nervous system.  
 
Mitochondria in human brain physiology  
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Bioenergetics 
Despite representing only 2–3% of total body weight, the human brain consumes 
around 25% of the daily intake of glucose (Clarke and Sokoloff, 1999). These requirements 
are even higher during development, as the brains of infants utilize more than 40% of the 
basal metabolic rate (Goyal et al., 2014). Mitochondria might therefore be particularly 
relevant for the function of the central nervous system (CNS) given its high energy demands. 
In fact, cell types with high bioenergetic needs -like skeletal muscle and heart muscle- 
commonly rely on OxPhos metabolism (Kunz, 2001; Padrão et al., 2011). 
Nonetheless, bioenergetics alone may not be sufficient to explain the importance of 
mitochondria for CNS physiology. Other cell types with high energetic needs do not appear to 
rely on mitochondrial respiration. This is the case of proliferative cells like cancer cells and 
pluripotent stem cells (PSCs), which instead exhibit a glycolytic-dependent metabolism 
(Prigione et al., 2010; Vander Heiden et al., 2009). In these proliferative cells with high 
necessity for anabolic growth, there is an energy re-routing leading to enhanced rates of 
glycolysis and pentose phosphate pathway (PPP) as well as reduced entry of pyruvate into 
mitochondria (Prigione et al., 2015). This bears the crucial advantages of supporting the 
biosynthetic needs and maintaining low oxidative stress levels through the reduction of 
OxPhos-mediated ROS production and the increase of the level of the PPP-derived 
antioxidant glutathione (GSH) (Stincone et al., 2015). However, neuronal cells do not rely on 
glycolysis, since they favor a metabolic program that fully depends on mitochondrial 
respiration, despite its potential detrimental consequences on redox homeostasis (Figure 1). 
The metabolic profile of the cells can influence the epigenetic state, which refers to 
chromatin reorganization leading to a defined gene expression program in the absence of 
changes in the DNA sequence (Gut and Verdin, 2013). Metabolism-driven chromatin 
regulation is crucial for cellular plasticity, as it dictates the changes required to modulate the 
cell fate identity as it is in the case of reprogramming to iPSCs (Mathieu and Ruohola-Baker, 
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2017). Epigenetics is tightly regulated upon neural fate commitment (Imamura et al., 2014). 
However, the contribution of metabolism in the epigenetic regulation of neural fate remains to 
be investigated. 
  
Redox and protein homeostasis 
Oxygen is an important substrate for cellular energy production (Semenza, 2007). The 
use of oxygen for cellular energy generation is, however, not without risks. During the 
transfer of electrons in the mitochondrial respiratory chain, electrons may escape and 
prematurely react with oxygen to form ROS (Turrens, 2003). Oxidative stress, which can be 
described as an imbalance between the production of ROS and the capacity of the cell to 
counteract ROS, results in macromolecular damage (oxidizing of lipids, proteins, and nucleic 
acids) (Stadtman, 2006). This can in turn cause necrotic or apoptotic cell death (Balaban et al., 
2005) (Figure 1).  
The adult human brain consumes about 20% of the oxygen that is inspired at rest 
(Erecińska and Silver, 2001). Hence, neuronal cells need to be prepared to balance ROS with 
antioxidant defenses. To this aim, the production of NADPH within the oxidative branch of 
the PPP is critical, as it is needed for the generation of GSH (Stincone et al., 2015) (Figure 1). 
Any imbalance of this fine equilibrium may contribute to oxidative stress and 
neurodegeneration (Lin and Beal, 2006). 
Among the detrimental consequences of oxidative stress, there is protein oxidation, 
which can be associated with the loss of protein function and the cytoplasmic accumulation of 
protein aggregates. Protein defects and protein aggregation may also be caused by an 
impairment of protein clearance pathways, including the ubiquitin-proteasome system and 
autophagy. Although it is still debated which kind of protein states (large aggregates or small 
oligomers) are the most toxic species, a disruption of protein homeostasis -in short 
proteostasis- is harmful to the cells (Díaz-Villanueva et al., 2015; Ruan et al., 2017). Aberrant 
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proteostasis could particularly affect neuronal cells, which are long-lived cells and may 
therefore sustain increased accumulation of damaged proteins over time. In accordance, the 
presence of intracellular protein aggregates is a common feature of neurodegenerative 
diseases (Lim and Yue, 2015).  
 
Calcium homeostasis 
Calcium homeostasis is essential for excitable cells like neurons that require 
cytoplasmic calcium for the regulation of neurotransmitter release (Neher and Sakaba, 2008). 
Calcium-activated potassium channels regulate plasma membrane polarization and cellular 
excitability as synaptic transmission requires the initial entrance of calcium into the cells (Sah 
and Louise Faber, 2002).  
In order to avoid toxic consequences of calcium overload and to allow the cells to 
become excitable again, cytoplasmic calcium needs to be quickly buffered. This process is 
energetically demanding and relies on calcium-ATPases in the plasma membrane and in the 
endoplasmic reticulum (ER). The ER can efficiently clear low amounts of cytoplasmic 
calcium. When the amount of calcium increases in the cytoplasm, or within a 
microenvironment of the cytoplasm, mitochondria become responsible for the clearance. 
Mitochondria are in fact low-specificity high-capacity buffers, which means that they can take 
up the largest amount of cytoplasmic calcium once it reaches a certain level (Williams et al., 
2013). The MMP is the driver for this mitochondrial calcium uptake (Rizzuto et al., 2012). 
Given their motility, mitochondria can travel to areas of high calcium concentration in order 
to reduce it to normal level (Wang and Schwarz, 2009). Mitochondrial calcium uptake is in 
turn beneficial for cellular energetics, since calcium within mitochondria induces ATP 
production via activation of calcium-dependent NADH dehydrogenases (McCormack and 
Denton, 1990; Wan et al., 1989). 
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The fine tuning of calcium homeostasis by mitochondria is critical, as mitochondrial 
calcium overload can trigger cell death through the opening of the permeability transition pore 
(PTP), which consists of dimers of ATP synthase (Giorgio et al., 2013) (Figure 1). Defective 
mitochondrial calcium handling is therefore highly detrimental for neuronal cells, and may 
contribute to the neuronal cell death observed in neurodegenerative diseases (Abeti and 
Abramov, 2015) and in mitochondrial disorders (Abramov et al., 2010).  
 
Mitochondrial dynamics 
Mitochondria are highly dynamic organelles and continuously change their shape 
through the processes of fusion and fission (Chan, 2006). The plasticity and dynamics of the 
mitochondrial network enable mitochondria to reach all subcellular regions and to respond to 
local needs by distributing calcium, ATP, and ROS, thereby contributing to the maintenance 
of cellular homeostasis (van der Bliek et al., 2013). The energetic status of the cells and the 
MMP are important regulator of mitochondrial fusion, as loss of MMP results into 
mitochondrial fragmentation (Hoppins and Nunnari, 2009). 
Mitochondrial dynamics is critical for highly polarized cells like neurons, where 
energy needs to be supplied to regions that are distant from the cell body (Hollenbeck, 2005). 
Accordingly, pathogenic mutations that disrupt proteins involved in fusion and fission cause 
neurological diseases (Burté et al., 2015). At the same time, disturbed mitochondrial 
dynamics has been implicated in the pathogenesis of many neurodegenerative disorders (Chen 
and Chan, 2009). 
The degradation of dysfunctional mitochondria plays an important physiological role. 
Mitochondrial fission can generate a defective mitochondrial daughter unit that is eliminated 
by the autophagic machinery through a process called mitophagy (Twig and Shirihai, 2011). 
The degradation of impaired mitochondria is essential in maintaining the quality control for 
correct cellular function. This control may be particularly relevant for long-living cells like 
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neurons that have to maintain tight homeostatic control for a long time in order to avoid the 
persistence of dysfunctional mitochondria (de Castro et al., 2010).  
 
Neuron-glia interactions 
Glial cells are active components of synapses and contribute to neurotransmission 
(Auld and Robitaille, 2003; Kettenmann et al., 2013). Glial cells also provide metabolic 
support. Within the CNS, astrocytes regulate the flux of energy substrates to neurons, thereby 
generating a physiological metabolic compartmentalization (Pellerin and Magistretti 2012).  
Astrocytes take up glucose and convert into lactate via glycolysis, and neurons take up 
the astrocyte-produced lactate and use it for ATP generation via OxPhos (Pellerin and 
Magistretti, 1994; Pellerin and Magistretti 2012). This leaves neurons free to use glucose in 
the PPP pathway for antioxidant defenses via GSH production (Herrero-Mendez et al., 2009) 
(Figure 1). This dependency on PPP-based utilization of glucose in neuronal cells may make 
neurons more sensitive to mitochondrial dysfunction, as they are unable to increase glycolysis 
and glycolytic-based utilization of glucose. Neurons may even release their damaged 
mitochondria to take up healthy ones from astrocytes (Hayakawa et al., 2016). 
Despite their apparent glycolytic metabolism, glia may also need active mitochondria. 
In fact, it has been suggested that the lactate that is released from glia may come not only 
from glycolysis-derived pyruvate but also from mitochondria-derived malate converted into 
pyruvate (Dienel and McKenna, 2014) (Figure 1). Moreover, the communication between 
astrocytes and neurons occurs through elaborated “calcium waves”, whose homeostatic 
control requires functional mitochondria (Bazargani and Attwell, 2016; Jackson and 
Robinson, 2015; Skupin et al., 2010).  
 
Mitochondria in human brain pathology 
Neurodegenerative diseases  
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Neurodegenerative diseases are a group of disorders characterized by progressive 
degeneration of cells of the nervous system. Neurodegenerative diseases include Alzheimer’s 
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and 
Huntington’s disease (HD). All of these neurodegenerative diseases show a specific 
accumulation of dysfunctional mitochondria (Burté et al., 2015; de Castro et al., 2010; Johri 
and Beal, 2012; Lin and Beal, 2006) (Figure 2).  
In AD, mitochondrial dysfunction appears to precede Aβ deposition (Moreira et al., 
2010; Swerdlow et al., 2010). The accumulation of Aβ-species leads to metabolic 
dysfunctions in the tricarboxylic acid (TCA) cycle and in the activity of mitochondrial 
complex IV (Lustbader et al., 2004; Morán et al., 2012). Defects in mitochondrial dynamics 
and mitochondrial biogenesis may also occur (Reddy et al., 2012; Sheng et al., 2012). Finally, 
reduced glucose metabolism in the brain is a recognized early feature of AD (Calsolaro and 
Edison, 2016), as also seen in a fly model of AD where reduced Aβ toxicity was achieved by 
counteracting glucose hypometabolism (Niccoli et al., 2016).  
The involvement of mitochondrial dysfunction in PD has been assumed since the early 
1980s, when drug addicts were observed to develop parkinsonism from the drug by-product 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which causes inhibition of the 
mitochondrial complex I (Winklhofer and Haass, 2010). Complex I inhibition via MTPT or 
rotenone is now commonly employed to generate animal models of PD. Deficiency in 
complex I activity was detected in the substantia nigra pars compacta (SNpc) of PD patients 
(Schapira et al., 1990) and oxidative stress has been observed in post-mortem studies of 
sporadic PD (Michel et al., 2014). Finally, most of the genes associated with familial PD 
encode for proteins that belong to mitochondria or that have a direct link to mitochondrial 
function, morphology, or dynamics (Bose and Beal, 2016).  
In familial ALS, mutations in the gene superoxide dismutase 1 (SOD1) cause defective 
mitochondrial function, morphology, and distribution (Tafuri et al., 2015). Impaired 
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bioenergetics, mitochondrial calcium homeostasis, mitochondrial apoptosis, and axonal 
transport of mitochondria have all been reported in sporadic ALS (Shi et al., 2010). These 
defects also occur in peripheral cells, as ALS-derived fibroblasts display reduced MMP and 
decreased mitochondrial content (Kirk et al., 2014).  
There is evidence for overall bioenergetic defects in HD, as indicated by weight loss 
and increased energy expenditure that HD patients exhibit in spite of sustained calorie intake 
(Lodi et al., 2000). Although largely cytosolic, mutant huntingtin (HTT) can associate with 
the outer mitochondrial membrane. There, it impairs mitochondrial protein import and 
proteostasis via cytoplasmic protein accumulation (Ruan et al., 2017; Yano et al., 2014) and 
affects mitochondrial dynamics by binding with the mitochondrial fission GTPase, dynamin-
related protein-1 (DRP1), which induces mitochondrial fragmentation (Song et al., 2011). 
Finally, reduced activity of the respiratory complexes II, III and IV, impaired calcium 
homeostasis, and oxidative damage have all been implicated in HD pathogenesis (Panov et 
al., 2002; Sorolla et al., 2008). 
 
Psychiatric diseases 
Mitochondrial defects have been observed in many psychiatric conditions, including 
schizophrenia (SCZ), bipolar disorder (BPD), autism spectrum disorder (ASD), and alcohol 
use disorder (AUD) (Marazziti et al., 2011).  
In SCZ altered metabolic pathways have been found in brain tissue from schizophrenic 
patients, pointing towards a disturbance in brain energy metabolism and oxidative stress as 
contributing causes of SCZ (Michel et al., 2011; Prabakaran et al., 2004). The mitochondrial 
defects in SCZ vary within different brain regions (Roberts, 2017). The perturbation of 
mitochondrial network dynamics in SCZ may also contribute to the dysfunction of immuno-
inflammatory pathways that are associated with the origin on SCZ (Rajasekaran et al., 2015). 
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BPD has been proposed to result from a phasic dysregulation of mitochondrial 
function (Morris et al., 2017), thereby leading to recurrent fluctuations in mood and energy. 
The reduced pH observed during manic phases may in fact be a consequence of lactate 
accumulation caused by defective mitochondrial metabolism in neurons (Weber et al., 2013). 
In accordance, complex I activity has been found decreased in the prefrontal cortex of BPD 
patients (Andreazza et al., 2010) and depressed BPD patients showed reduced glucose brain 
metabolism (Hosokawa et al., 2009).  
The prevalence of mitochondrial dysfunction was reported to be higher in ASD 
compared to the general population (Rossignol and Frye, 2012; Hollis et al., 2017). Almost 
one third of ASD patients have increased lactate-to-pyruvate ratio (Correia et al., 2006). Post-
mortem brain tissues studies identified decreased activity of RC complexes, elevated ROS, 
and mtDNA mutations in individuals with ASD (Chauhan et al., 2011; Tang et al., 2013).  RC 
defects included complexes II and V in frontal lobe, temporal lobe, cortex, and cerebellum 
(Chauhan et al., 2011) and complexes I, III, IV and V in temporal lobe (Tang et al., 2013). 
Additionally, decreased pyruvate dehydrogenase activity has been associated with reduced 
activity in RC complexes I and II and increased copy number variations (CNVs) in the genes 
encoding for these complexes (Gu et al., 2013).  
In the context of AUD, it is known that ethanol intoxication has detrimental effects on 
mitochondria of CNS cells (Hoek et al., 2002). Mitochondria might also play a role in the 
establishment of the alcohol addiction behavior. The abnormally increased release of 
dopamine (DA) in the ventral tegmental area, which is a key region regulating central reward, 
depends on calcium homeostasis, and therefore may be influenced by mitochondrial 
functionality. Reduced DA release, and subsequently reduced alcohol consumption, were 
observed in mice upon administration of the liver hormone FGF21 (Talukdar et al., 2016), 
suggesting the presence of metabolic-based regulatory mechanisms for glucose and alcohol-




Mitochondrial diseases are a group of inherited metabolic disorders caused by OxPhos 
defects due to mutations in the nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) 
(Koopman et al., 2012). Unlike mitochondrial dysfunctions in neurological and psychiatric 
diseases, which may be secondary within the pathogenic mechanism, in mitochondrial 
disorders the mitochondrial defects are primary and of clear genetic origin. Mutations in over 
150 genes encoding for proteins of the mitochondrial respiratory chain have been associated 
with mitochondrial disorders (Vafai and Mootha, 2012). Although any organ or tissue can be 
affected, patients generally display neurological symptoms (Carelli and Chan, 2014; 
Koopman et al., 2013; McFarland et al., 2010).  
Neurological conditions caused by mtDNA mutations include Leber’s hereditary optic 
neuropathy (LOHN), mitochondrial encephalomyopathy with lactic acidosis and stroke-like 
episodes (MELAS), and neurogenic weakness, ataxia and retinitis pigmentosa (NARP).  
The most severe mitochondrial disease is Leigh syndrome (LS), a progressive 
encephalopathy with basal ganglia involvement. LS can be caused by several mutations of 
OxPhos components encoded by nDNA, such as NDUFS4 (complex I) and SURF1 (assembly 
factor of complex IV), or by mtDNA, like MT-ATP6 (complex V) and MT-ND2 (complex I) 
(Koopman et al., 2013). 
 
Mitochondria in PSC models of neurological and psychiatric diseases 
PSC-based disease modeling 
Human pluripotent stem cells (PSCs) include human embryonic stem cells (ESCs) and 
human induced pluripotent stem cells (iPSCs), which are obtained from somatic cells through 
the process of cellular reprogramming (Takahashi et al., 2007). iPSCs exhibit mitochondrial 
properties that are comparable to those of ESCs, regardless of the donor age of the parental 
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somatic cells (Bukowiecki et al., 2014; Xu et al., 2013). Upon conversion of iPSCs into neural 
cells, a mitochondrial maturation occurs, as mitochondria develop into an elongated network 
and the metabolism shifts from glycolysis towards OxPhos (Choi et al., 2015; Lorenz et al., 
2017). A number of iPSC-based models have been generated to investigate 
neurodegenerative, psychiatric, and mitochondrial disorders. Several of these models 
identified mitochondrial dysfunctions in the patient-derived neural cells (Figure 2).   
In the context of AD, neurons generated from iPSCs derived from patients with 
sporadic AD showed defective expression of genes involved in mitochondrial function and 
respiratory chain, including nuclear-encoded OxPhos genes (Hossini et al., 2015). Oxidative 
stress has been detected also in neurons and astrocytes derived from familial AD patients 
(Kondo et al., 2013). 
For familial PD patients, defects in mitochondrial function and bioenergetics have 
been found in neural progenitor cells (NPCs) (Flierl et al., 2014), while mature neurons 
displayed dysfunctional mitochondrial dynamics and reduced response to oxidative stress 
(Cooper et al., 2012; Nguyen et al., 2011) and reduced mitochondrial volume fraction 
(Shaltouki et al., 2015). Decreased mitochondrial spare-respiration and increased production 
of basal ROS and increased mtDNA damage have been also described in familial PD-derived 
neurons (Ryan et al., 2013; Sanders et al., 2014). Mitochondrial morphology and 
mitochondrial motility appeared disrupted in human motor neurons obtained from ALS 
patients carrying mutant SOD1 (Kiskinis et al., 2014).  
NPCs derived from HD iPSCs displayed decreased intracellular ATP levels compared 
to control NPCs (HD iPSC Consortium, 2012). Aberrant bioenergetics in HD NPCs was also 
confirmed using genome-edited iPSCs (An et al., 2012; Xu et al., 2017). iPSC-derived 
neurons from HD patients showed store-operated channel (SOC)-mediated calcium 
dysregulation (Nekrasov et al., 2016) and impaired mitophagy (Guo et al., 2016). A small 
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molecule compound (P110-TAT) was found to inhibit mtHTT-induced mitochondrial 
fragmentation and to increase cell viability in HD patient-derived neurons (Guo et al., 2013). 
In the context of psychiatric disorders, iPSC-derived NPCs from SCZ patients 
exhibited increased oxidative stress (Brennand et al., 2015), and dissipation of MMP together 
with perturbations of the mitochondrial network (Robicsek et al., 2013). Transfer of isolated 
normal mitochondria into iPSCs from SCZ patients rescued the defective neuronal 
differentiation, suggesting a direct effect of mitochondrial dysfunction in the pathogenesis of 
SCZ (Robicsek et al., 2017).  
Hippocampal dentate gyrus-like neurons derived from iPSCs of BPD patients showed 
mitochondrial abnormalities, including upregulated mitochondrial gene expression, reduced 
organelle size, and higher MMP (Mertens et al., 2015a). Interestingly, these defects were 
rescued by lithium only if the cells were derived from BDP patients that responded clinically 
to lithium treatment. 
For mitochondrial disorders, iPSCs lines have been generated and used to dissect the 
extent of neuronal dysfunction. In the case of MELAS, impaired mitochondrial dynamics and 
complex I degradation were observed during iPSC differentiation into neuronal-like cells 
(Hämäläinen et al., 2013). Defective bioenergetics was also found in NPCs carrying mtDNA 
mutations that cause MELAS and LS (Ma et al., 2015). NPCs and neurons carrying a 
mutation in the MT-ATP6 gene showed aberrant bioenergetics, which was improved in 
response to mTOR inhibition (Zheng et al., 2016). NPCs and neurons carrying a different MT-
ATP6 mutation exhibited defective mitochondrial calcium homeostasis and abnormally 
increased MMP, which were rescued following treatment with the PDE5 inhibitor avanafil 




Genome editing tools, including zinc finger nuclease (ZFNs), transcriptional activator-
like effector nucleases (TALENs), and the leading-edge clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas9 system have become significantly important in PSC-
based disease modeling (Kim and Kim, 2014). Their use allow the generation of so-called 
isogenic control PSC lines with respect to any disease-causing nDNA mutation (Hockemeyer 
and Jaenisch, 2016). This can be accomplished by either correcting the mutation in patient-
derived iPSCs or by introducing the mutation into control PSCs (Grobarczyk et al., 2015). 
Given the heterogeneity of PSC lines, the use of isogenic iPSC controls can help uncovering 
the functional differences that are solely caused by the specific mutation (Ross and Akimov, 
2014). This approach has been successfully employed in the context of several iPSC models 
of neurological diseases (Figure 2).  
TALEN technology has been used in iPSCs from familial AD patients to generate an 
allelic series of mutations in the gene Presenilin 1 (PS1) (Woodruff et al., 2013). In iPSCs 
from familial PD, ZFNs were used to correct mutations in the gene LRRK2 (Reinhardt et al., 
2013; Sanders et al., 2014) and in alpha-synuclein gene SNCA (Soldner et al., 2011) 
CRISPR/Cas9 system was employed to generate isogenic PSCs carrying specific disease-
associated genetic risk variants associated with sporadic PD (Soldner et al., 2016). For 
familial ALS, SOD1 mutations were corrected in iPSCs using ZNF-based editing (Kiskinis et 
al., 2014) and CRISPR/Cas9 (Wang et al., 2017). CRISPR/Cas9 was also used to repair a 
mutation in the gene C9ORF72 in familial ALS iPSCs (Mutihac et al., 2015). In the context of 
HD, the expanded CAG repeat in the HTT gene was corrected with homologous 
recombination (An et al., 2012) and, more recently, with CRISPR/Cas9 technology (Xu et al., 
2017). 
In the context of mutations in the mtDNA, however, genome editing is still not 
practicable. The generation of isogenic lines remains a major challenge for  iPSC-based 
modeling of mitochondrial DNA disorders (Inak et al., 2017). There are only two solutions 
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available for mtDNA mutations. First, to replace the whole mitochondria via somatic cell 
nuclear transfer (SCNT) (Ma et al., 2015). This approach, however, does not correct a specific 
mutation but creates a novel cell carrying a mismatch between the original nDNA and 
mtDNA, which in itself may cause altered cellular phenotypes (Sterneckert et al., 2014). In 
fact, the introduction of a distinct mtDNA into a recipient cell can cause extensive 
transcriptional reprogramming (Picard et al., 2015). Second, to decrease the level of mutation 
by selective elimination of the mutated mtDNA molecules (Gammage et al., 2014; Moraes, 
2014). This technology however is only applicable for heteroplasmic mtDNA mutations, 
where a mixture of wild type and mutated mtDNA is present in the cells.  
It is interesting to notice that a change in the level of heteroplasmic mtDNA mutations 
can also occur naturally during the derivation of iPSCs from somatic cells (Prigione et al., 
2011). This effect can lead to the spontaneous derivation of iPSCs with reduced mtDNA 
mutation levels that may act as isogenic control lines (Folmes et al., 2013; Fujikura et al., 
2012; Hämäläinen et al., 2013; Kodaira et al., 2015; Ma et al., 2015; Perales-Clemente et al., 
2016).  
 
Challenges and future directions 
PSC-based disease modeling is now widely used and can be coupled with 
conventional disease modeling approaches. In the context of neurological, psychiatric, and 
mitochondrial diseases, human PSCs are becoming particularly relevant given that animal 
models may not be available or may not fully recapitulate the disease phenotypes (Sandoe and 
Eggan, 2013). In particular, the use of PSCs is shedding light on the importance of 
mitochondrial function for brain pathologies, as highlighted above. Nonetheless, critical 
challenges still remain.  
One of the major issues is the degree of maturation of PSC-derived neurons and glia 
(Tao and Zhang, 2016). A long time of in vitro culture is needed in order for these cells to 
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reach a certain degree of maturity. The use of PSC-derived neurons and glia is therefore 
highly costly and time-consuming. Overexpression of neural specific transcription factors can 
be used to speed up the process (Zhang et al., 2013). However, the generated neurons and glia 
may still be more resembling cells of the fetal rather than adult brain. This is also the case for 
PSC-derived three dimensional brain organoids, which are starting to be used given their 
more faithful mirroring of brain development (Lancaster et al., 2013; Paşca et al., 2015; Yang 
and Ng, 2017). Furthermore, due to the epigenetic reprogramming occurring during the 
generation of iPSCs, aging-related features may be erased. The use of neurons and glia 
directly derived from fibroblasts may thus represent a promising strategy to allow capturing 
aging-related phenomena (Mertens et al., 2015b). However, this approach may not yet be 
ideal for disease modeling applications due to limited number of neurons and glia generated. 
Alternatively, aging may be accelerated in vitro using progerin overexpression (Miller et al., 
2013) or by inducing cellular stresses (Studer et al., 2015).  
Among the most interesting applications of PSC-derived cells of the nervous system is 
their use in drug discovery platforms. In order to reach this goal, however, several aspects 
need to be met including cost-effective cell generation and high reproducibility (Avior et al., 
2016). The differentiation of iPSCs into post-mitotic neurons is in fact costly and time-
consuming and thus not amenable yet for high-throughput compound screening studies. On 
the other hand, iPSC-derived neural progenitor cells (NPCs) are homogenous and easy to 
expand and their transcriptional profile resemble that of NPCs residing in the human adult 
brain (Lorenz et al., 2017). iPSC-derived NPCs may thus potentially be suitable for large-
scale screenings, once disease-specific and relevant phenotypes have been identified and 
confirmed both in NPCs and post-mitotic neurons (Inak et al., 2017). The gene editing of 
human PSCs still presents numerous challenges. Most importantly, there is the risk to 
introduce off-target effects that may mask or alter the actual disease phenotypes (Hockemeyer 
and Jaenisch, 2016). Secondarily, this approach may be highly valuable only for monogenic 
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diseases, while complex sporadic forms may be hard to tackle. Finally, editing of mtDNA still 
remains to be demonstrated.  
Future studies should apply genome-editing technologies in iPSCs to target nuclear 
genes regulating mitochondrial function. By investigating the consequences on PSC-derived 
neurons and glia, it may be possible to gain important new knowledge regarding the role of 
mitochondria in human brain function (Figure 2).  
Overall, the use of PSCs may help unveiling the contribution of mitochondria in the 
healthy and diseased human brain. This information may ultimately lead to improved 
therapies for debilitating neurological and psychiatric diseases. 
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Figure 1. Mitochondria in human brain cells. Mitochondria contribute to the physiological 
functionality of human neurons and glia. Their roles include the control of cellular 
bioenergetics, redox balance, apoptosis, and calcium homeostasis (see text for details). 
Abbreviations: PPP: pentose phosphate pathway; GSH: glutathione; Glucose-6P: glucose-6-
phosphate; ROS: reactive oxygen species; TCA cycle: tricarboxylic acid cycle; Acetyl-CoA: 
acetyl coenzyme A; ATP: adenosine triphosphate. 
Figure 2. Probing mitochondrial brain function with PSCs and genome editing. The use 
of human PSCs, combining patient-derived material with precise genome engineering, can 
allow dissecting the contribution of mitochondria to human brain function. Numbers in 
brackets refer to the following references: (1) Hossini et al., 2015; (2) Kondo et al., 2013; (3) 
Woodruff et al., 2013; (4) Fierli et al., 2014; (5) Shaltouki et al., 2015; (6) Cooper et al., 2012; 
(7) Nguyen et al., 2011; (8) Ryan et al., 2013; (9) Sanders et al., 2014; (10) Reinhardt et al., 
2013; (11) Soldner et al., 2011; (12) Soldner et al., 2016; (13) Kiskinis et al., 2014; (14) Wang 
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